Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1CXBG | ISIN: FR0010557264 | Ticker-Symbol: A8D
Tradegate
06.06.25 | 08:40
1,126 Euro
+0,72 % +0,008
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
AB SCIENCE SA Chart 1 Jahr
5-Tage-Chart
AB SCIENCE SA 5-Tage-Chart
RealtimeGeldBriefZeit
1,1401,15216:51
1,1421,15216:39

Aktuelle News zur AB SCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.05.AB Science announces the settlement delivery of its latest capital increase for €1.8 million103PRESS RELEASE AB SCIENCE ANNOUNCES THE SETTLEMENT DELIVERY OF ITS LATEST CAPITAL INCREASE FOR €1.8 MILLION Paris, May 23, 2025, 8am CET AB Science S.A. (the "Company" or "AB Science", Euronext...
► Artikel lesen
20.05.AB Science announces the successful completion of a EUR 1.8 million private placement2
19.05.AB Science Receives Chinese Patent Protecting Masitinib To Treat Covid-19 Until 2041; Stock Up278BEIJING (dpa-AFX) - French pharmaceutical company AB Science SA (ABSCF.PK) announced Monday that it has received Chinese patent protecting Masitinib in the treatment of Covid-19 until April...
► Artikel lesen
19.05.AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection113PRESS RELEASE AB SCIENCE RECEIVES CHINESE PATENT PROTECTING MASITINIB IN THE TREATMENT OF COVID-19 UNTIL 2041, ADDING ONE MORE INDICATION WITH LONG TERM INTELLECTUAL PROPERTY PROTECTION Paris, May...
► Artikel lesen
AB SCIENCE Aktie jetzt für 0€ handeln
15.05.AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib2
12.05.AB Science Posts Narrower Loss In FY24232BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - AB Science SA (ABSCF.PK) posted a fiscal 2024 net loss of 7.8 millon euros compared to a loss of 12.0 million euros, prior year. Basic loss per share was...
► Artikel lesen
12.05.AB Science reports its revenues for the year 2024 and provides an update on its activities832PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2024 AND THE KEY EVENTS OF THE PERIOD Financial and corporate situation Operating deficit of 6,1 million euros...
► Artikel lesen
05.05.AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting1
01.05.AB Science will publish its 2024 annual financial report on May 9, 20252
23.04.AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia268PRESS RELEASE EUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA Paris, April 23, 2025, 6.45pm CET AB Science...
► Artikel lesen
14.04.AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease238PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE Paris, April 14, 2025, 6pm CET AB Science SA (Euronext...
► Artikel lesen
04.03.AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch174PRESS RELEASE ARTICLE FROM THE LEADING PUBLICATION LIFE SCIENCES MAGAZINE FEATURING AB SCIENCE'S MASITINIB AND ITS PHASE 3 PRINCIPAL INVESTIGATOR, THE NEUROLOGIST PATRICK VERMERSCH Paris, March 04...
► Artikel lesen
29.01.AB Science today provides an update on its masitinib platform5
24.01.AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET2
17.12.24AB Science provides a summary of the webcast held on December 16, 202413
11.12.24AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET5
28.10.24AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease2.313PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB'S...
► Artikel lesen
17.10.24AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS213PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 17 October, 2024, 7.30pm...
► Artikel lesen
10.10.24AB Science: Revenues for the first half of 2024 and update on AB Science's activities396PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIOD Clinical development Masitinib platform: Ongoing re-examination by...
► Artikel lesen
26.09.24AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement205PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE MICROTUBULE PROGRAM AB8939 AND IN PARTICULAR THE ABILITY OF AB8939 TO GENERATE RESPONSE ON MECOM REARRANGEMENT Paris, 26 September 2024, 8.30am CET...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1